A list released by the guangdong pharmaceutical trading center on May 2, May 8, showed that up to 1, 004 of the drugs were broken. Li mingda, the chairman of a guangdong public hospital drug procurement company, has been asked more than once for reasons not to provide drugs. 

 

"We have not produced this drug in our workshop for a year or two, because we can't buy it at all." On May 4, li mingda told the daily business news that the company is really having a hard time making money. Some selling drugs, despite the amount, but several years of rising costs has eroded the originally some profit, by a small number of market monopoly of active pharmaceutical ingredients, is to let the enterprise hard to survive. 

 

The price of some raw materials has nearly eight times 

 

In chemical industry, chemical pharmaceuticals companies in the upstream, preparation in the downstream enterprises, active pharmaceutical ingredients supply enterprise does not directly to preparation, but through some medical company. 

 

Ming-da li company is in the downstream industry chain, he told the "daily economic news" reporter, API monopoly is a major cause of lead to cheap medicine outages. "Take vitamin B1 for example, the price of one kilogram is 230 yuan to 280 yuan, now over 1800 yuan, sometimes even to 2,000 yuan, it's ridiculous." 

 

'at the beginning, there were still some stock in the factory,' Mr. Li said. 'it didn't take long to finish, and we had to order from the supplier.' But every time he goes to the factory where he makes the raw material, the other side says that the goods have been ordered out, even if there is nothing to buy. He knew in his heart that several large companies had bought the raw materials and had them sold. 

 

Because of the strict examination and approval, there are not many pharmaceutical factories that have obtained original pharmaceutical production qualifications. Inspect bureau deputy director of the national development and reform commission, price Li Qingceng introduction, in 1500 kinds of chemical pharmaceuticals, 50 kinds of API a company only can produce qualified approval of 44 API only two firms can produce, 40 kinds of API only three can produce. And given that the pollution pressures are large and the margins are small, the number of factories that actually produce is likely to be even smaller. In the case of the drug monopoly, which has been published in recent years, the majority of the companies that have been monopolized by the monopoly of the raw materials are single digits, and the actual production is usually only two or three. 

 

"Daily economic news" reporter found that after check total bureau of national food drug safety database trouble ming-da li as the raw material of the drug, there are more than 700 production enterprises in the country. It is the sharp contrast between supply that gives some people a chance. But Mr Li declined to say more about the monopolists, telling reporters repeatedly that "the raw material monopoly is so strong that many varieties are the same." 

 

The lamenting drug companies are difficult to survive 

 

In addition to the very helpless of raw material prices, ming-da li also found that the production workshop of the cost of upgrading, product upgrading fee and rent, labor costs increasing every year, has already put his business. 

 

Calculated brushstroke zhang ming-da li to the reporter, in order to pass the standard of GMP certification by the end of 2015 (drug production quality management specification), he shall, in accordance with the standard of each workshop upgrade, the cost of a workshop is 30 million yuan to 30 million yuan. 

 

Last year, the state food and drug safety administration requires that all drug complete consistency evaluation, a product upgrade costs about $7 million, the first need to upgrade the approximately 50 kinds of products, is expected to invest 350 million yuan. 

 

It is understood that the new GMP standards have raised the cost of pharmaceutical companies in some way. GMP standards is to let the unqualified in the process of drug production to minimize risk and concluded, including the workshop, ground, equipment, personnel, training, health, air and water purification has rules. According to industry estimates, if the original plant and equipment does not meet the new GMP certification standard, it must invest in another new plant and equipment, cost over 100 million yuan. 

 

Ming-da li told the "daily economic news" reporter, in order to ease the pressure, he has transformed workshop amortization expenses in five years and is now the first batch of consistency evaluation of drug upgrade to input more than three. The company has more than 90 varieties, with just over half of the first batch of upgrades, and a further uphill upgrade. At the same time, labor costs are rising year by year. 

 

"It's very difficult to get people a 20 per cent wage this year." Ming-da li said that a new employee now cost is 3700 yuan per month to 3700 yuan, but also the bag eats encase, a production line to six or seven employees, it is also a lot of overhead. But over the years, the price of drug sales has not only risen, but also has been declining, with fewer and fewer profits each year. 

 

He sent the journalist, for example, according to the company a box of glucose injection production cost is 1.8 yuan, but the price is only 1.2 yuan, this means that as long as to produce loss, enterprise can not supply, the "black list", then to accept punishment. "There is no way to do it, and the Chinese are not able to do it. The medical industry is getting sadder."